F-box and leucine rich repeat protein 13Genealiases: CFAP169 · DRC6 · Fbl13
Q-omics provides the consensus-scored FBXL13 profile across patient tissues and cancer cell-line models. FBXL13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FBXL13 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FBXL13 RNA expression shows 19,958 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and COAD as cancer lineages where FBXL13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL13 survival associations across molecular data types. FBXL13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL13 RNA expression–survival associations across cancer types. High FBXL13 expression shows unfavorable associations in KIRP, LGG and KIRC, but favorable associations in SKCM, HNSC and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for FBXL13 RNA expression.
This table summarizes FBXL13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXL13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL13 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, HNSC, CHOL and KIRP. The COAD box plot shows higher FBXL13 RNA expression in tumor versus normal tissue (log2 FC = +0.307, t-test p < 0.001).
This table shows molecular features associated with FBXL13 in patient tissues and cancer cell lines. In patient samples, FBXL13 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
